Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD6001 in advanced solid tumors
NCT05230290Phase 1Completed
- Sponsor
- Shanghai Kanda Biotechnology
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- IgG Antibodies, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KD6001 in solid tumor (advanced stage), sponsored by Shanghai Kanda Biotechnology. Primary endpoints: Number of Participants with Dose Limiting Toxicities, Incidence and nature of participants with adverse events and 1 more. Started Sep 2020; status: completed.
02
Drugs
KD6001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05230290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230290.